<DOC>
	<DOCNO>NCT00813865</DOCNO>
	<brief_summary>This study measure long-term safety AT2101 effect hemoglobin , platelet , liver spleen volume , bone density . This study also look effect AT2101 beta-glucocerebrosidase level , glucosylceramide level , blood marker Gaucher disease .</brief_summary>
	<brief_title>A Long-Term Extension Study AT2101 Type 1 Gaucher Patients</brief_title>
	<detailed_description>This open-label , long-term extension study design ass long-term safety , efficacy pharmacodynamics AT2101 patient type 1 Gaucher disease successfully complete Study GAU-CL-202 . Participants may enter study immediately upon completion Study GAU-CL-202 , late time point . Each participant continue receive AT2101 dose level regimen previous study . Study visit occur every 3 month . At every visit , safety evaluation perform blood sample collect pharmacodynamic test . At completion every year treatment study , early termination visit , participant undergo comprehensive physical examination , MRIs liver , spleen femoral bone , DEXA scan femoral bone lumbar spine , complete SF-36 questionnaire . Duration treatment depend time participant 's enrollment study . Participants contact approximately 1 month study completion assessment adverse event .</detailed_description>
	<mesh_term>Gaucher Disease</mesh_term>
	<criteria>Male female subject , 18 year age older Completed study GAUCL202 significant protocol violation safety concern Clinically stable Has receive enzyme replacement therapy ( ERT ) substrate reduction therapy ( SRT ) past 12 month willing initiate ERT SRT study participation All subject reproductive potential require practice acceptable method contraception Provides write informed consent participate study During screen period ( Visit 1 ) , clinically significant finding would compromise safety subject , preclude subject complete study deem investigator A clinically significant disease , severe complication Gaucher disease , serious intercurrent illness may preclude participation study , opinion Investigator History allergy sensitivity study drug excipients , include prior serious allergic reaction iminosugars ( e.g. , miglustat ) Pacemaker contraindication MRI scan Pregnant breastfeed Presence sequelae gastrointestinal , liver , kidney disease , condition know interfere absorption , distribution , metabolism , excretion drug Subject otherwise unsuitable study opinion investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>